Business Wire

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% ...
Seeking Alpha

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced new data from multiple analyses which reinforce that Livdelzi ® (seladelpar), known as Lyvdelzi ® in the European ...
Business Insider

Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management

(RTTNews) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with primary biliary ...
Business Wire

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s Trodelvy ® in Advanced Breast Cancer

WIN-B (NCT06612203) is a Phase Ib/II, multi-center investigator-initiated trial, evaluating the safety and preliminary efficacy of combining Debiopharm's selective WEE1 inhibitor, Debio 0123 and ...
Nasdaq

FDA Halts Gilead's HIV Trials Over Safety Signal

(RTTNews) - The U.S. Food and Drug Administration Tuesday announced that it has placed a clinical hold on Gilead Sciences' (GILD) investigational HIV trials combining GS-1720 and GS-4182. This action ...
Benzinga.com

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend

Gilead Sciences Inc. (NASDAQ:GILD) announced on Friday data from the Phase 3 ASCENT-07 study of Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy in HR+/HER2-negative metastatic breast cancer ...
Insider Monkey

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold ...
NEJM Catalyst

Advancing Patient Safety and Health Care Quality — Bridging Research, Policy, and Implementation

Despite decades of patient safety initiatives, preventable harm remains prevalent in health care. This article posits that a ...
Seeking Alpha

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Results demonstrate the safety profile of Livdelzi remains robust, with no treatment-related serious adverse events (SAEs) reported throughout the study duration. The exposure-adjusted incidence of ...